New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
11:53 EDTVASC, BSXVascular Solutions: Injunction against Boston Scientific's Guidezilla vacated
Vascular Solutions (VASC) announced that a three judge panel of the U.S. Court of Appeals for the Federal Circuit vacated the preliminary injunction that was previously issued by the District Court for the District of Minnesota effective January 13 against Boston Scientific's (BMY) Guidezilla guide extension catheter. In its one paragraph opinion vacating the injunction, the court noted that a preliminary injunction is a "drastic and extraordinary remedy that is not to be routinely granted" and "at this stage of the case the record is too incomplete . . . to warrant the grant of a preliminary injunction." The court's ruling on the preliminary injunction does not affect the underlying patent litigation, which is currently scheduled to be ready for trial on or after March 2015 in the District Court for the District of Minnesota.
News For VASC;BSX From The Last 14 Days
Check below for free stories on VASC;BSX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
06:32 EDTBSXJ&J dispute with Boston Scientific looks set to go to trial, NY Times says
Subscribe for More Information
July 24, 2014
10:56 EDTBSXStocks with call strike movement; NRG BSX
NRG Energy (NRG) January 35 call option implied volatility decreased 2% to 24, NRG Energy Boston Scientific (BSX) January 15 call option implied volatility decreased 2% to 25 according to IVolatility.
08:28 EDTBSXBoston Scientific sees FY operating margin approaching 20%
Subscribe for More Information
07:04 EDTBSXBoston Scientific raises FY14 adjusted EPS to 79c-83c from 77c-82c
Subscribe for More Information
07:02 EDTBSXBoston Scientific sees Q3 adjusted EPS 18c-20c, consensus 19c
Subscribe for More Information
07:02 EDTBSXBoston Scientific reports Q2 Rhythm Management revenue growth of 7%
Subscribe for More Information
07:01 EDTBSXBoston Scientific reports Q2 adjusted EPS 21c, consensus 19c
Reports Q2 revenue $1.87B, consensus $1.87B
July 23, 2014
17:10 EDTBSXBoston Scientific receives CE Mark for Agent Drug Coated Balloon
Subscribe for More Information
15:30 EDTBSXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
July 22, 2014
16:20 EDTVASCVascular Solutions sees Q3 GAAP EPS 19c-20c, consensus 18c
Sees Q3 revenue $30.5M-$31.5M, consensus $31.05M. Q3 revenue view represents growth of approximately 11% from $28.0M in the Q3 of FY13. The company's net earnings guidance for the Q3 includes $800,000 in non-cash stock-based compensation, $400,000 in amortization of intangibles, $370,000 for the U.S. medical device excise tax, and an assumed 36% effective income tax rate.
16:18 EDTVASCVascular Solutions raises FY14 GAAP EPS view to73c-77c from 71c-75c
Vascular Solutions is raising the bottom-end of its net revenue guidance for FY14 to $123M, resulting in a new range of $123M- $125M. The mid-point of the new range represents an increase of 12% from $110.5M in 2013. Previously, the company's revenue guidance range for 2014 was $121M-$125M. Consensus is for FY14 revenue $123.22M. Vascular Solutions is also raising its GAAP earnings guidance for 2014 to a range of $0.73-$0.77 per share, representing an increase of 12%-18% over the $0.65 reported in 2013. The company's previous EPS guidance range for 2014 was $0.71-$0.75. Included in the company's 2014 earnings guidance are $3.8M in non-cash stock-based compensation, $1.6M in amortization of intangibles, between $1.4M-$1.5M for the U.S. medical device excise tax, and an assumed 36% tax rate. Consensus is for FY14 EPS 72c.
16:14 EDTVASCVascular Solutions reports Q2 adj. EPS 20c, consensus 18c
Subscribe for More Information
08:25 EDTBSXBoston Scientific risk/reward favorable into Q2 results, says RBC Capital
Subscribe for More Information
July 21, 2014
16:38 EDTBSXBoston Scientific receives FDA approval for REBEL Platinum Stent system
Subscribe for More Information
July 14, 2014
19:19 EDTBSXBoston Scientific receives CE Mark for 25 mm Lotus Valve System
Subscribe for More Information
09:02 EDTBSXBoston Scientific receives CE mark for Ranger drug-coated balloon
Boston Scientific has received CE Mark for the Ranger Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Balloon provides physicians with an additional option to treat peripheral artery disease, delivering an anti-stenotic drug to diseased vascular tissue while leaving no permanent implant behind.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use